InMed Pharmaceuticals Inc.
For the period ended Mar 31, 2025. Filed May 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 12, 2025
INM$15.56+17.8%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
| March 31, | June 30, | |
|---|---|---|
| 2025 | 2024 | |
| Unaudited | ||
| $ | $ | |
| ASSETS | ||
| Current | ||
| Cash and cash equivalents | 4,679,826 | 6,571,610 |
| Short-term investments | 40,582 | 43,064 |
| Accounts receivable (less provision for credit losses of $nil in each of March 31, 2025 and June 30, 2024) | 367,813 | 352,838 |
| Inventories, net | 813,970 | 1,244,324 |
| Prepaids and other current assets | 507,872 | 477,749 |
| Total current assets | 6,410,063 | 8,689,585 |
| Non-Current | ||
| Property, equipment and operating lease right-of-use (“ROU”) assets, net | 1,108,662 | 1,249,999 |
| Intangible assets, net | 1,661,109 | 1,783,198 |
| Other assets | 100,000 | 100,000 |
| Total Assets | 9,279,834 | 11,822,782 |
| LIABILITIES AND SHAREHOLDERS’ EQUITY | ||
| Current | ||
| Accounts payable and accrued liabilities | 1,409,715 | 1,654,011 |
| Current portion of operating lease obligations | 429,247 | 317,797 |
| Total current liabilities | 1,838,962 | 1,971,808 |
| Non-current | ||
| Operating lease obligations, net of current portion | 419,347 | 644,865 |
| Total Liabilities | 2,258,309 | 2,616,673 |
| Commitments and Contingencies (Note 11) | ||
| Shareholders’ Equity | ||
| Common Shares, unlimited authorized shares: 1,207,186 and 445,908, as of March 31, 2025 and June 30, 2024, respectively, issued and outstanding | 87,457,095 | 82,784,400 |
| Additional paid-in capital | 34,885,442 | 35,368,899 |
| Accumulated deficit | (115,449,581) | (109,075,759) |
| Accumulated other comprehensive income | 128,569 | 128,569 |
| Total Shareholders’ Equity | 7,021,525 | 9,206,109 |
| Total Liabilities and Shareholders’ Equity | 9,279,834 | 11,822,782 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.